Status:
UNKNOWN
Transarterial Chemoembolization With Lipiodol in the Treatment of Initial Unresectable Gastric Cancer (GC)
Lead Sponsor:
Gang Wu
Conditions:
Gastric Cancer
Embolization
Eligibility:
All Genders
18-80 years
Phase:
PHASE2
Brief Summary
This is a prospective, open-labelled study to evaluate the efficacy and safety of sequential transarterial chemoembolization with lipiodol and neoadjuvant chemotherapy in the treatment of Initial unre...
Eligibility Criteria
Inclusion
- Pathological and imaging diagnosis of gastric adenocarcinoma with initial unresectable R0;
- Age (18-80 years old) and gender are not limited;
- No extragastric organ transfer;
- No serious diseases of the heart, liver, lung, kidney and other organs;
- Expected survival time \> 3 months;
- Physical performance status score ECOG ≤1 point;
- Females of reproductive age must have a negative pregnancy test; or male and female patients must agree to use effective contraception during treatment and within 1 year thereafter.
Exclusion
- Poor coagulation function, INR\>1.5, or ongoing anticoagulation therapy or known bleeding diseases;
- WBC \<3000/mm3 or platelet count \<50000/mm3;
- AST and/or ALT \> 3 times the upper limit of normal;
- Comorbidities or social environment that can cause subjects to fail to follow the research plan or even endanger patient safety;
- The patient has other primary tumors.
Key Trial Info
Start Date :
June 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2025
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT05361161
Start Date
June 1 2022
End Date
December 1 2025
Last Update
May 24 2022
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.